Vivalto Partners announces a significant investment in Laboratoires Delbert to support the company’s development in the field of essential and orphan drugs. The historical investors – Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF – are also reinvesting in the transaction.

Vivalto Partners, a management company set up in 2021 by Daniel Caille, founder of the Vivalto Santé group of clinics, announces the closing of a significant investment in Laboratoires Delbert alongside its two founders Marc Childs and Thierry Hoffmann, their management team and all the financial investors who acquired a stake in the company in 2020 (Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF). This investment will enable Laboratoires Delbert to enter a new phase of development, giving them the means to support the strong growth of their business, and to contribute to meeting drug shortages.

Acquired in 2013 and since managed by Marc Childs and Thierry Hoffmann, Laboratoires Delbert specializes in acquiring and maintaining on the market drugs of major therapeutic interest or essential as defined by the World Health Organization. Active in three major therapeutic areas (infectiology, central nervous system and oncology), Laboratoires Delbert has recognized expertise in securing the production chain, enabling it to limit the risks of supply disruptions and position itself as a benchmark partner for regulatory authorities and major pharmaceutical groups alike. These skills have also enabled the company to expand into orphan diseases by repositioning molecules already on the market.

Drawing on its expertise and network in the healthcare sector, Vivalto Partners intends to support Laboratoires Delbert in a new stage of its development, enabling it to strengthen its position, particularly internationally and in new therapeutic indications. What’s more, like Vivalto Santé, Laboratoires Delbert has made the ambitious decision to obtain Entreprise à Mission status in the near future.

Marc Childs and Thierry Hoffmann, said: “We are delighted to welcome Vivalto Partners, a new financial partner specialized in the healthcare sector and endowed with a genuine entrepreneurial spirit. With the management team and our long-standing shareholders (Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF) continuing the adventure we embarked upon three years ago, we will be able to reach a new milestone and continue to cultivate our vocation: to maintain access for patients to certain essential medicines neglected by the market, and to revive and enrich pharmaceutical specialties for the benefit of as many people as possible”.

Daniel Caille, Chairman of Vivalto Partners, adds: “ We are sincerely delighted to support Marc and Thierry and their formidable team in the development of their product portfolio in France and abroad. Laboratoires Delbert has demonstrated its indispensable role in keeping vital drugs on the market for the treatment of numerous pathologies. This is perfectly in line with the values we wish to uphold by investing in healthcare: caring for life. . »

Participants in the operation :

Laboratoires Delbert: Marc Childs, Thierry Hoffmann, Eric Fidelin, Rohald Meyer
Vivalto Partners: Daniel Caille, Sébastien Alauzet, Charles-Eric François, Georges Weill
Sagard NewGen: Bérangère Barbe, Agnès Huyghues Despointes, Louis Gosselin
Socadif Capital Investissement: Thierry Antonini, Emmanuel David
IDIA Capital Investissement: Nicolas Lambert, Jean Lebreton, Faora Narayanan
MACSF: Roger Caniard
Board of Directors : Edmond de Rothschild (Arnaud Petit, Anastasia Saldi, Augustin Hay, Tristan Gonnord, Paul Assaël, Arnaud Jolly, Thibault Blanc) – Neuflize OBC (Jean-Christophe Liard) – LPA (Raphaël Chantelot, Maxime Ponsan, Mathieu Selva-Roudon, Céline Guo) – Roland Berger (Frédéric Thomas) – KPMG (Antoine Bernabeu)
Vivalto Partners advisors: Fieldfisher (Pascal Squercioni, Natalia Toribio, Lorette Cassard) – CMS (Arnaud Hugot, Antoine Melchior) – Cepton (Matthias Bucher) – Alvarez & Marsal (Frédéric Steiner, Guillaume Descamps)
Financing banks: Caisse Régionale de Crédit Agricole Mutuel de Paris et d’Ile de France (Issam El Fehham, Gregory Leguet, Nicolas Bouchet), Crédit Agricole Corporate and Investment Bank, Artemid, Société Générale, Banque Populaire Rives de Paris, Neuflize OBC
PIK : Bpifrance Investissement, CIC Private Debt

About Laboratoires Delbert

Laboratoires Delbert’s mission is to maintain access to medicines of major therapeutic interest (MITM) for patients. Every year, Laboratoires Delbert acquires new drugs whose future is in jeopardy. Laboratoires Delbert is concentrating its efforts on finding production sites in Europe. With the help of its staff and the support of clinicians, galenicists, engineers and chemists, Laboratoires Delbert brings these drugs back to life, to guarantee their availability to the medical profession and to patients. Laboratoires Delbert achieved sales of almost €35 million in 2022.

About Vivalto Partners

Founded in 2021 in Paris by Daniel Caille, Vivalto Partners is a management company approved by the Autorité des Marchés Financiers (AMF). The team supports profitable European companies that contribute to the quality of healthcare. The fund has a strong ESG focus, as well as a responsible approach to value creation. The management company is a member of the France Invest association, and will be a signatory of the United Nations Principles for Responsible Investment.
For further information, www.vivaltopartners.com

Laboratoires Delbert is pleased to announce that it has signed the Responsible Purchasing and Supplier Relations (RFAR) charter.

Committed since its creation to responsible approaches with its suppliers, on January 23, 2023 Laboratoires Delbert formalized these commitments by becoming a signatory to the “Responsible Supplier Relations and Purchasing” Charter steered by the Médiateur des Entreprises and the CNA (Conseil National des Achats).

This approach is part of Laboratoires Delbert’s ongoing efforts to integrate environmental and social priorities into its activities. Through this document, Laboratoires Delbert commits to 10 principles for responsible purchasing.

10 COMMITMENTS TO RESPONSIBLE PURCHASING

01.

Ensure a responsible financial relationship with suppliers.

02.

Maintain a respectful relationship with all suppliers, favoring the development of collaborative relationships.

03.

Identify and manage reciprocal dependencies with suppliers.

04.

Involve signatory organizations in their industry.

05.

Appreciate all life-cycle costs and impacts.

06.

Integrate environmental and social responsibility issues.

07.

Ensure the territorial responsibility of its organization.

08.

The professionalism and ethics of the purchasing function.

09.

A Purchasing function responsible for overall management of supplier relations.

10.

A “supplier relations” mediator to smooth internal and external relations.

Article published on Lemonde.fr, December 2, 2022.

Since 2013, the pharmaceutical company has been fighting to breathe new life into essential old molecules threatened with disappearing from the therapeutic arsenal. With each new dossier that lands on its desk, the rule is always the same.

“We check that the medicine meets a clear medical need, then assess whether its development is technically feasible in France or Europe. If we’re 85% sure, we go ahead”, explains Thierry Hoffmann, Managing Director of Laboratoires Delbert.